As one of the most aggressive and lethal malignant tumors,the 5-year survival rate of oesophageal cancer is less than 20%.[1]There are two main pathological subtypes of esophageal cancer:esophageal squamous cell carci...As one of the most aggressive and lethal malignant tumors,the 5-year survival rate of oesophageal cancer is less than 20%.[1]There are two main pathological subtypes of esophageal cancer:esophageal squamous cell carcinoma(ESCC)and esophageal adenocarcinoma.[1]In China,more than 95%of esophageal cancer is ESCC.Encourag-ingly,cancer immunotherapy has entered a new era recently with the discovery of drugs that interfere with specific immune checkpoints.Moreover,due to the good effect of immunotherapy in squamous cell carcinoma,it may be a new strategy for ESCC treatment in the future.展开更多
基金the grants from the National Key Research and Development Program of China(No.2018YFC1313105)the Institutional Fundamental Research Funds(No.2018PT32033).
文摘As one of the most aggressive and lethal malignant tumors,the 5-year survival rate of oesophageal cancer is less than 20%.[1]There are two main pathological subtypes of esophageal cancer:esophageal squamous cell carcinoma(ESCC)and esophageal adenocarcinoma.[1]In China,more than 95%of esophageal cancer is ESCC.Encourag-ingly,cancer immunotherapy has entered a new era recently with the discovery of drugs that interfere with specific immune checkpoints.Moreover,due to the good effect of immunotherapy in squamous cell carcinoma,it may be a new strategy for ESCC treatment in the future.
